{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-001980","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.706112+00:00","generated_at":"2026-06-20T17:50:16.595695+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Theravance Biopharma highlights YUPELRI growth, $250M buyback progress, and ampreloxetine Phase 3 start","bullets":["YUPELRI achieved all-time high net sales and profit in Q2 and Q3 2022; expects continued Q4 growth.","$250M capital return program ~50% completed as of 12/31/2022; ~$95M GSK buyback and ~$33M open market repurchases.","Ampreloxetine Phase 3 CYPRESS trial in MSA patients with nOH to start Q1 2023; orphan drug submission planned.","Targeting Non-GAAP profitability by 2H 2023; $50M milestone if TRELEGY sales reach ~$2.86B in 2023.","Sale of TRELEGY royalty interests for $1.1B upfront eliminated all debt; financial restructuring completed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-001980","json":"https://secwatch.observer/filing/0001104659-23-001980.json","markdown":"https://secwatch.observer/filing/0001104659-23-001980.md","text":"https://secwatch.observer/filing/0001104659-23-001980.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465923001980/0001104659-23-001980-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465923001980/tm232391d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:50:16.595695+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}